



LUPIN

February 7, 2019

BSE Limited

Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

Kind Attn.: Ms. Zarana Shah

Dear Madam,

Re: Clarification /Confirmation on news item appearing in www.moneycontrol.com.

We refer to your email dated February 7, 2019, seeking clarifications as regards the news item which appeared on www.moneycontrol.com today, captioned 'Lupin falls 4% as US FDA issues observations to Pithampur unit'.

We wish to state that, the Company, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, had already intimated your Exchange, on January 26, 2019, that the US FDA inspection, carried out between January 14 and January 25, 2019, at Pithampur Unit - 2 (Indore) facility, closed with 6 observations.

Copies of our covering letter and the captioned Press Release both dated January 26, 2019, are enclosed for your ready reference.

Trust we have clarified the matter.

Thanking you,

Yours faithfully,

For LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY**



Encl.: a/a

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com



January 26, 2019

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards completion of USFDA inspection carried out at the Company's Pithampur Unit -2 (Indore) facility.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For Lupin Limited

R. V. Satam

1/26/2019

X R. V. SATAM

R. V. Satam

Company Secretary Signed by: RAJVARDHAN VISHNU SATAM



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

U.S. FDA completes inspection of Lupin's Pithampur Unit-2 (Indore) facility

Mumbai, January 26, 2019: Pharma major Lupin announced today the completion of the United States Food and Drug Administration (U.S. FDA) inspection carried out at its Pithampur Unit -2 (Indore) facility. The inspection was carried out between January 14 and January 25, 2019.

The inspection at Pithampur Unit-2 (Indore) closed with 6 observations. The Company is confident of addressing the observations satisfactorily.

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 13th largest generics pharmaceutical company in terms of market capitalization (30th September 2018, Bloomberg) and the 8th largest generics pharmaceutical company in terms of revenues (30th June 2018, Bloomberg LTM) globally. The Company is the 3rd largest pharmaceutical player in the US by prescriptions for the Total Market (IQVIA MAT September 2018); 3rd largest Indian pharmaceutical company by global revenues (30th June 2018, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan (IQVIA MAT September 2018) and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2018).

For the financial year ended 31st March, 2018, Lupin's Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran
VP – Corporate Communications
Email: poojathakran@lupin.com
Ph: +91-22-66402531 / 8291013225

Arvind Bothra
Head – Investor Relations
Email:
arvindbothra@lupin.com
Ph: +91-22-66402137

**Safe Harbor Statement*